Drug
Acalabrutinib clinical trials
Also written ACP-196 and Calquence.
Includes 1 study of Acalabrutinib maleate anhydrous.
Keep track of what changes. Save the acalabrutinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
124 studies that test it; most in 2021 (23)
| Year | Studies |
|---|---|
| 2014 | 8 |
| 2015 | 12 |
| 2016 | 7 |
| 2017 | 5 |
| 2018 | 6 |
| 2019 | 12 |
| 2020 | 21 |
| 2021 | 23 |
| 2022 | 7 |
| 2023 | 9 |
| 2024 | 6 |
| 2025 | 5 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 55 · Other 69
Acerta Pharma BV (35) · AstraZeneca (14) · M.D. Anderson Cancer Center (9) · City of Hope Medical Center (5) · German CLL Study Group (3) · Fred Hutchinson Cancer Center (2) · Mayo Clinic (2) · Washington University School of Medicine (2)
Often tested with
Tested in the same studies.
Venetoclax (16) · Obinutuzumab (16) · Rituximab (14) · Tafasitamab (5) · Lenalidomide (4) · Bendamustine (3) · Ibrutinib (3) · Ublituximab (2)
Studies
Open first, then newest update. How each study uses acalabrutinib is read from its arms, and is right about nine times in ten.
Testing it · 124
- Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 TrialRecruitingPhase 2Fred Hutchinson Cancer CenterNCT04941716Written as Acalabrutinib
- MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without ObinutuzumabRecruitingPhase 2AstraZenecaNCT07024706Written as Acalabrutinib
- Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell LymphomaRecruitingPhase 2National Cancer Institute (NCI)NCT04002947Written as Acalabrutinib
- Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular LymphomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT04404088Written as Acalabrutinib
- A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHLRecruitingPhase 1/2BioInvent International ABNCT03571568Written as Acalabrutinib
- Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingPhase 2Mayo ClinicNCT03516617Written as Acalabrutinib
- Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCLRecruitingPhase 2AstraZenecaNCT05952024Written as Acalabrutinib
- Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart FailureRecruitingPhase 4AstraZenecaNCT06651970Written as Acalabrutinib
- Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT04169737Written as Acalabrutinib
- A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLLRecruitingPhase 3German CLL Study GroupNCT05197192Written as Acalabrutinib
- A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.RecruitingPhase 3Ascentage Pharma Group Inc.NCT06319456Written as Acalabrutinib
- Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell LymphomaRecruitingPhase 3Universität des SaarlandesNCT05820841Written as R-miniCHOP + Acalabrutinib
- Acalabrutinib Maleate and Bortezomib for Patients With HLA AntibodiesNot yet recruitingPhase 3The First Affiliated Hospital of Soochow UniversityNCT07635511Written as Acalabrutinib maleate
- Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaNot yet recruitingPhase 2City of Hope Medical CenterNCT07582159Written as Acalabrutinib
- A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)RecruitingPhase 3AbbVieNCT06428019Written as Acalabrutinib
- Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell LymphomaRecruitingPhase 1/2Jonsson Comprehensive Cancer CenterNCT05256641Written as Acalabrutinib
- Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin LymphomasRecruitingPhase 2Emory UniversityNCT04883437Written as Acalabrutinib
- Avo In R/R And Previously Untreated MCLRecruitingPhase 1/2Austin I KimNCT04855695Written as Acalabrutinib
- Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLRecruitingPhase 2Zulfa OmerNCT07014917Written as Acalabrutinib
- Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell LymphomaRecruitingPhase 2City of Hope Medical CenterNCT06054776Written as Acalabrutinib
See all 124 studies that test acalabrutinib →
Given in every arm · 15 — acalabrutinib is usual care beside what is tested
- A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell MalignanciesRecruitingPhase 1/2AstraZenecaNCT06564038Written as Acalabrutinib
- Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 StudyRecruitingPhase 2M.D. Anderson Cancer CenterNCT07257055Written as Acalabrutinib
- Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic LeukemiaRecruitingPhase 2Ohio State University Comprehensive Cancer CenterNCT05336812Written as Acalabrutinib
- Mosunetuzumab for CLL MRD ClearanceRecruitingPhase 1/2Inhye AhnNCT07052695Written as Acalabrutinib
- A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)RecruitingPhase 2VA Office of Research and DevelopmentNCT06520098Written as Ibrutinib, Acalabrutinib, Zanubrutinib
- Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin LymphomaActive, not recruitingPhase 1/2Acerta Pharma BVNCT02180711Written as acalabrutinib
- A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell MalignanciesCompletedPhase 1AstraZenecaNCT03198650Written as Acalabrutinib
- Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCLActive, not recruitingPhase 2Weill Medical College of Cornell UniversityNCT03863184Written as Acalabrutinib
- Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLLCompletedPhase 1Acerta Pharma BVNCT02296918Written as acalabrutinib
- A Study Of The Selective PKC-β Inhibitor MS- 553TerminatedPhase 1/2MingSight Pharmaceuticals, IncNCT03492125Written as acalabrutinib
- AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood CancerCompletedPhase 1/2AstraZenecaNCT04630756Written as Acalabrutinib
- Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)CompletedPhase 1Acerta Pharma BVNCT03527147Written as Acalabrutinib
- Acalabrutinib Plus RICE for Relapsed/Refractory DLBCLStatus unknownPhase 2Swedish Medical CenterNCT03736616Written as Acalabrutinib
- A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult ParticipantsCompletedPhase 1Acerta Pharma BVNCT05140096Written as Acalabrutinib
- A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy ParticipantsCompletedPhase 1AstraZenecaNCT04489797Written as Acalabrutinib
As the comparator · 4 — what is tested is compared with acalabrutinib
- A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06136559Written as Acalabrutinib
- A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic LeukemiaRecruitingPhase 3BeOne MedicinesNCT07277231Written as Acalabrutinib
- A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingPhase 3Guangzhou Lupeng Pharmaceutical Company LTD.NCT07377578Written as Acalabrutinib
- Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)Active, not recruitingPhase 3Loxo Oncology, Inc.NCT04662255Written as Acalabrutinib
Codes
What other systems call acalabrutinib · ClinicalTrials.gg INT000401
- MeSH (NLM) C000604908acalabrutinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) I42748ELQWACALABRUTINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1986808Confirmed FDA, Wikidata
- Wikidata Q23668732acalabrutinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C113442AcalabrutinibOne source FDA
- DrugBank DB11703One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000604908 | acalabrutinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | I42748ELQW | ACALABRUTINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1986808 | — | Confirmed FDA, Wikidata |
| Wikidata | Q23668732 | acalabrutinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C113442 | Acalabrutinib | One source FDA |
| DrugBank | DB11703 | — | One source Wikidata |
Also registered as acalabrutinib maleate monohydrate (UNII 9GP2BPG9NS).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.